Founded in 2015, EMPE Diagnostics emerged from the scientific excellence of Sweden’s Karolinska Institutet. We are dedicated to addressing the global burden of tuberculosis (TB) through diagnostics that are fast, accurate, and accessible.
Our mission extends beyond detection alone: by combining TB identification with antibiotic resistance profiling in single test, we aim to outpace antimicrobial resistance (AMR) and ensure patients receive the right treatment from the very first diagnostic test.
Our vision, a world free from TB, enabled by timely diagnosis for everyone, everywhere.
With a strong focus on India – where over 2.7 million new TB cases occur each year – EMPE Diagnostics plays a key role in the fight against TB. Our CDSCO approved product is manufactured at scale in our Hyderabad facility, and we are proud to be ISO 13485:2016 certified and compliant with “Made in India” requirements, enabling participation in government programs and contracts.
EMPE Diagnostics is proud to be supported by leading global organizations and investors who share our commitment to eliminating TB. We have received grant funding from both the European Innovation Council (EIC) and the Gates Foundation—becoming the first company to be backed by both these prestigious institutions.
